Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment
- First Online:
- Cite this article as:
- Werner de Castro, G.R., Neves, F.S., Pereira, I.A. et al. Rheumatol Int (2012) 32: 1313. doi:10.1007/s00296-011-1799-9
- 261 Downloads
Tumoral necrosis factor alpha blockers are very efficient in the treatment of many inflammatory systemic diseases, including rheumatoid arthritis and psoriasis. However, a paradoxical arouse of psoriasiform lesions may occur in a few patients taking anti-TNFα. The etiology of this rare side effect is still a mystery, and its treatment may be difficult. The authors report the resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after the use of high vitamin D3 doses for the treatment of vitamin D deficiency. This is the first report of resolution of anti-TNFα-induced psoriasiform lesions by high doses of vitamin D3 in a patient with rheumatoid arthritis and vitamin D deficiency. This case raises interesting questions on the role of vitamin D deficiency in the pathogenesis of this side effect and on the possible usefulness of high-dose vitamin D3 in its treatment.